Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-PD-1 monoclonal antibody

Serplulimab (Specialist drug)

Brand names: Hetronifly

Serplulimab is an intravenous anti-PD-1 monoclonal antibody (immune checkpoint inhibitor) used as a specialist anticancer treatment, including in small-cell lung cancer.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks the programmed cell death protein 1 (PD-1) receptor on T cells, releasing inhibitory signalling and restoring T-cell-mediated anti-tumour immune responses.

Prescribing in practice

  • As a checkpoint inhibitor it can cause serious immune-related adverse effects affecting many organs (including colitis, pneumonitis, hepatitis and endocrinopathies) that may require corticosteroids and treatment interruption.
  • Infusion-related reactions can occur and administration is restricted to specialist oncology services.
  • Endocrine effects such as thyroid dysfunction may be delayed and require ongoing vigilance.

Monitoring

Monitor liver, renal, thyroid and other endocrine function and watch for immune-related adverse effects throughout and after treatment.

Counselling the patient

  • Report new or worsening symptoms such as persistent diarrhoea, breathlessness, cough or unusual fatigue promptly.
  • Carry an alert card and tell any healthcare professional you are receiving immunotherapy.
  • Attend all monitoring appointments, including after treatment has finished.

Evidence & guidelines

Use is guided by the SPC and randomised trial evidence for PD-1 checkpoint inhibitors in the relevant tumour types.

Reference: NICE; SmPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways